Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

idarubicin hydrochloride

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Topoisomerase II inhibitor, DNA cross linking agent

Related drugs:

‹

oxaliplatin (57)

cisplatin liposomal (0)

demplatin pegraglumer (0)

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

oxaliplatin (57)

cisplatin liposomal (0)

demplatin pegraglumer (0)

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride Sensitive : A2	cytarabine + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	clofarabine + idarubicin hydrochloride Sensitive: A2 - Guideline clofarabine + idarubicin hydrochloride Sensitive : A2	clofarabine + idarubicin hydrochloride Sensitive: A2 - Guideline clofarabine + idarubicin hydrochloride Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2	cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C3 – Early Trials cytarabine + idarubicin hydrochloride Sensitive : C3	cytarabine + idarubicin hydrochloride Sensitive: C3 – Early Trials cytarabine + idarubicin hydrochloride Sensitive : C3
DNMT3A R882	Acute Myelogenous Leukemia	DNMT3A R882	Acute Myelogenous Leukemia	idarubicin hydrochloride Sensitive: C3 – Early Trials idarubicin hydrochloride Sensitive : C3	idarubicin hydrochloride Sensitive: C3 – Early Trials idarubicin hydrochloride Sensitive : C3
CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	paclitaxel + cytarabine + idarubicin hydrochloride Sensitive: C4 – Case Studies paclitaxel + cytarabine + idarubicin hydrochloride Sensitive : C4	paclitaxel + cytarabine + idarubicin hydrochloride Sensitive: C4 – Case Studies paclitaxel + cytarabine + idarubicin hydrochloride Sensitive : C4
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + tretinoin Sensitive : C4	cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + tretinoin Sensitive : C4
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D
TOP2A amplification	Rectal Cancer	TOP2A amplification	Rectal Cancer	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D
PDE3A overexpression	Acute Myelogenous Leukemia	PDE3A overexpression	Acute Myelogenous Leukemia	idarubicin hydrochloride + anagrelide Sensitive: D – Preclinical idarubicin hydrochloride + anagrelide Sensitive : D	idarubicin hydrochloride + anagrelide Sensitive: D – Preclinical idarubicin hydrochloride + anagrelide Sensitive : D